Magliano DJ, Boyko EJ; IDF Diabetes Atlas 10th edition scientific committee. IDF DIABETES ATLAS [Internet]. 10th ed. Brussels: International Diabetes Federation; 2021. PMID: 35914061.

Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701.

Khunti K, Wolden ML, Thorsted BL, et al. Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people. Diabetes Care. 2013;36(11):3411–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Riddle MC. Insulin therapy in type 2 diabetes mellitus: a practical approach for primary care physicians and other healthcare professionals. J Am Osteopath Assoc. 2013;113(2):152–62.

Google Scholar 

Samajdar SS, Mukherjee S, Tripathi SK, Pal J, Joshi SR. Early initiation of insulin therapy in newly diagnosed patients with type 2 diabetes and exploring the legacy effect—a single-arm prospective observational study. Bengal Phys J. 2020;7(3):52–4.

Article  Google Scholar 

Matsuhisa M, Koyama M, Cheng X, et al. Efficacy and safety of insulin glargine 300 U/mL versus glargine 100 U/mL in Japanese adults with type 2 diabetes inadequately controlled on basal insulin with oral antidiabetic drugs: a randomized, controlled trial (EDITION JP 2). Diabetes Obes Metab. 2018;20(6):1299–307.

Google Scholar 

Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72.

Article  CAS  PubMed  Google Scholar 

Riddle MC, Bolli GB, Ziemen M, et al. New insulin glargine 300 units/mL versus glargine 100 units/mL in people with type 2 diabetes using oral agents and basal insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 2). Diabetes Care. 2015;38(12):2217–24.

Article  PubMed  Google Scholar 

Yki-Jarvinen H, Bergenstal R, Ziemen M, et al. New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin-naive people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3). Diabetes Obes Metab. 2015;17(4):386–94.

Article  Google Scholar 

Home PD, Bergenstal RM, Bolli GB, et al. New insulin glargine 300 U/mL versus glargine 100 U/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care. 2014;37(10):2755–62.

Article  PubMed  Google Scholar 

Ritzel R, Roussel R, Bolli GB, Vinet L, Brulle-Wohlhueter C, Glezer S, Yki-Järvinen H. Patient-level meta-analysis of the EDITION 1, 2 and 3 studies: glycaemic control and hypoglycaemia with new insulin glargine 300 U/ml versus glargine 100 U/ml in people with type 2 diabetes. Diabetes Obes Metab. 2015 Sep;17(9):859-67. doi: https://doi.org/10.1111/dom.12485. Epub 2015 Jun 16. PMID: 25929311; PMCID: PMC4676914.

Heise T, Mathieu C. Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Diabetes Obes Metab. 2017;19(1):3–12. https://doi.org/10.1111/dom.12782,indexedinPubmed:27593206.

Article  CAS  PubMed  Google Scholar 

Jindal S, et al. J Pak Med Assoc. 2020;70(3):547–51.

PubMed  Google Scholar 

Zhang Y, Frias JP, Chang AM, et al. Efficacy and safety of insulin glargine 300 U/mL versus 100 U/mL in insulin-naïve people with type 2 diabetes: results from the EDITION 3 trial. Diabetes Obes Metab. 2015;17(4):386–94. https://doi.org/10.1111/dom.12433.

Article  CAS  Google Scholar 

Duque N, Artime E, Romera I, Lebrec J, Díaz S, Rubio M, Sicras-Mainar A, Carretero-Anibarro E, Mundet X, Gorgojo-Martínez JJ, Reviriego J. Real-world use of insulin glargine U100 and U300 in insulin-naïve patients with type 2 diabetes mellitus: DosInGlar study. Advances in Therapy. 2021;38(7):3857–71.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pujante Alarcon P, Rodriguez Escobedo R, Garcia Urruzola F, Ares J, Manjon L, Sanchez Ragnarson C, Cacho L, Delgado E, Menendez Torre EL. Experience after switching from insulin glargine u100 to glargine U300 in patients with type 1 diabetes mellitus. A study after one year of treatment in real life. ENDOCRINOLOGIA DIABETES Y NUTRICION. 2019 Apr 1;66(4):210-6.

Vargas-Uricoechea H. Efficacy and safety of insulin glargine 300 U/mL versus 100 U/mL in diabetes mellitus: a comprehensive review of the literature. Journal of diabetes research. 2018 Oct;2018.

Joshi SR, Singh G, Marwah A, Mittra S, Suvarna VR, Athalye SN. Comparative clinical efficacy and safety of insulin glargine 300 U/ml (Toujeo) versus insulin glargine 100 U/ml in type 2 diabetes and type 1 diabetes: a systematic literature review and meta-analysis. Diabetes Obes Metab. 2023;25(6):1589–606.

Article  CAS  PubMed  Google Scholar 

Pfohl M, Jornayvaz FR, Fritsche A, Pscherer S, Anderten H, Pegelow K, Seufert J. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting. Diabetes, Obesity and Metabolism. 2020;22(5):759–66.

Article  CAS  Google Scholar 

Thomann R, Zechmann S, Alexander-David N, Jornayvaz FR. Real-world effectiveness of insulin glargine 300 initiation in Switzerland. Diabetes, Metabolic Syndrome and Obesity. 2020;3:2359–65.

Article  Google Scholar